Stay ahead in the medical device industry with this targeted course on the FDA’s rule for classifying prognostic assessment software of mild cognitive impairment (MCI) as a class II device. Learn specific compliance steps—premarket notification, clinical performance validation, software documentation, usability studies, and labeling. Gain insights into regulatory obligations, risk mitigation, and the impact of non-compliance. Get the detailed knowledge and actionable guidance needed to streamline 510(k) submissions and maintain lawful market access for innovative neurological software solutions.
In this course you will learn the following:
* Understand the FDA’s rationale for classifying prognostic assessment software of mild cognitive impairment as a class II device.
* Identify the special controls and general controls applicable to this device type.
* Implement the required steps for compliance, including premarket notification, performance validation, software documentation, labeling, and usability assessment.
* Recognize the legal and regulatory consequences of failing to comply with the final rule.
